Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock,

Vertex Pharmaceuticals (VRTX) is plummeting after disappointing trial results, headed for its worst day in four years

Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.11% to 5,970.